117 related articles for article (PubMed ID: 29795072)
21. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
[TBL] [Abstract][Full Text] [Related]
22. Short- and Long-term Pulmonary Outcome of Palivizumab in Children Born Extremely Prematurely.
Prais D; Kaplan E; Klinger G; Mussaffi H; Mei-Zahav M; Bar-Yishay E; Stafler P; Steuer G; Sirota L; Blau H
Chest; 2016 Mar; 149(3):801-8. PubMed ID: 26226546
[TBL] [Abstract][Full Text] [Related]
23. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
24. Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study.
Torchin H; Rousseau J; Marchand-Martin L; Truffert P; Jarreau PH; Ancel PY
Arch Pediatr; 2018 Feb; 25(2):89-94. PubMed ID: 29395887
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.
Nuijten MJ; Wittenberg W; Lebmeier M
Pharmacoeconomics; 2007; 25(1):55-71. PubMed ID: 17192118
[TBL] [Abstract][Full Text] [Related]
26. The association between respiratory syncytial virus infection and reactive airway disease.
Piedimonte G
Respir Med; 2002 Apr; 96 Suppl B():S25-9. PubMed ID: 11996401
[TBL] [Abstract][Full Text] [Related]
27. Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right?
Paes B; Carbonell-Estrany X
Expert Rev Anti Infect Ther; 2019 Apr; 17(4):211-222. PubMed ID: 30739513
[TBL] [Abstract][Full Text] [Related]
28. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].
Aliamovskaia GA; Keshinian ES
Vestn Ross Akad Med Nauk; 2012; (12):30, 32-4. PubMed ID: 23530423
[TBL] [Abstract][Full Text] [Related]
29. Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
Fanos V; Scarcella A; Puddu M; Gallini F; Tuminelli F; Bragetti P; Gallina MR; Quartulli L; Benincori N; Citro G; Via LD; Barera G; DI Luzio Paparatti U; Merolla R; Romano GV; Guida G; Silvestri M; Rossi GA
J Chemother; 2009 Jun; 21(3):302-10. PubMed ID: 19567351
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A
Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
[TBL] [Abstract][Full Text] [Related]
31. Association Between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections.
Grindeland CJ; Mauriello CT; Leedahl DD; Richter LM; Meyer AC
Pediatr Infect Dis J; 2016 Jul; 35(7):728-32. PubMed ID: 27078122
[TBL] [Abstract][Full Text] [Related]
32. Use of palivizumab with other infection control measures to control respiratory syncytial virus outbreaks in neonatal care units.
Hammoud MS; Al-Taiar A; Raina A; Elsori D; Al-Qabandi S; Al-Essa M
J Trop Pediatr; 2016 Oct; 62(5):409-14. PubMed ID: 27118823
[TBL] [Abstract][Full Text] [Related]
33. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
34. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden.
Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
Acta Paediatr; 2004 Nov; 93(11):1470-3. PubMed ID: 15513574
[TBL] [Abstract][Full Text] [Related]
35. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
[TBL] [Abstract][Full Text] [Related]
36. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
[TBL] [Abstract][Full Text] [Related]
37. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
[TBL] [Abstract][Full Text] [Related]
38. Prevention of syncytial respiratory virus infection with palivizumab: descriptive and comparative analysis after 12 years of use.
Narbona-Lopez E; Uberos J; Checa-Ros A; Rodriguez-Belmonte R; Muñoz-Hoyos A
Minerva Pediatr; 2018 Dec; 70(6):513-518. PubMed ID: 27598776
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
40. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
